American Bio Medica Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABMC research report →
Price Chart
About the company
American Bio Medica Corporation (ABMC) specializes in the development and distribution of lateral flow immunoassay tests, primarily designed for the rapid detection of drugs in both urine and oral fluid samples. Their extensive range of urine-based drug screening solutions includes the Rapid Drug Screen, capable of identifying between 2 and 10 substances; the RDS InCup, a convenient testing cup detecting 1 to 12 drugs; Rapid TOX, a cassette-based test for 1 to 10 drugs; and the Rapid TOX Cup II, another cup format that screens for 1 to 16 different drugs. Each product aims to swiftly determine the presence or absence of illicit substances.
- CEO
- Jean Neff
- IPO
- 1997
- Employees
- 16
- HQ
- Kinderhook, NY, US
Get TickerSpark's AI analysis on ABMC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.81K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.01
- P/B
- -0.00
- EV/EBITDA
- -1.90
- Div Yield
- 0.00%
- Gross Margin
- -21.14%
- Op Margin
- -136.04%
- Net Margin
- -154.44%
- ROE
- 85.90%
- ROIC
- 1254.55%
Latest fiscal year · YoY change
- Revenue
- $913.00K-58.8%
- Gross Profit
- $-193,000-135.2%
- Op Income
- $-1,242,000
- Net Income
- $-1,410,000-204.5%
- EPS
- $-0.03-172.2%
- OCF Growth
- -14.1%
- FCF Growth
- -14.1%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.12
- RSI (14)
- 52
- Avg Volume
- 746
No earnings-call transcripts are available for ABMC yet.
- Free Float
- 73.9%
- Shares Outstanding
- 48.10M
- Float Shares
- 35.55M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 21 | Sternberg Stuart | other | 0 |
| Oct 19, 21 | Sternberg Stuart | other | 0 |
| Jul 15, 21 | MORONEY JOHN J | sell | 495,500 |
| Jul 1, 20 | Davis Chaim | other | 35,461 |
| Jul 1, 20 | Neff Jean | other | 35,461 |
| Jul 1, 20 | Jerome Peter | other | 35,461 |
| Dec 31, 19 | MORONEY JOHN J | other | 0 |
| Apr 8, 20 | Davis Chaim | other | 7,751 |
| Apr 8, 20 | Jerome Peter | other | 7,751 |
| Apr 8, 20 | Neff Jean | other | 7,751 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ABMC coverage
Recent articles, reports, and earnings notes.
No research on ABMC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABMC report →American Bio Medica (OTCMKTS:ABMC) & Abbott Laboratories (NYSE:ABT) Head-To-Head Contrast
defenseworld.net · Feb 6
HealthToday Unveils eBook on Diabetes Management Featuring Renowned Nutrition Experts
https://feeds.newsfilecorp.com · May 20
American Beacon Launches Natural Resources ETF
etftrends.com · Feb 6
ABMC Reports Second Quarter 2021 Results
accesswire.com · Aug 18
American Beacon Advisors Unveils New American Beacon SSI Alternative Income Fund
businesswire.com · May 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.